Report
Jeroen Van Den Bossche ...
  • Thomas Vranken
  • Wim Hoste

Morning Note: AVTX NA, UCB BB

Avantium: Green light for FDCA plant; € 45m capital increase
UCB: Positive Ph III for rozan, first gMG shot is on target
Underlyings
10x Genomics Inc Class A

Avantium NV

Avantium NV Formerly known as Avantium Holding BV. Avantium NV, formerly Avantium Holding BV, is a company based in the Netherlands engaged in environmental research and development (R&D). The Company develops chemical technologies and production processes to convert bio-based feedstock into sustainable products. The Company's business comprises three segments: Catalysis, Renewable Chemistries, and YXY. Catalysis segment provides catalysis R&D services and systems to chemical, refinery and energy companies, utilizing its Flowrence Technology Platform to devise the appropriate catalyst testing solutions. Renewable Chemistries is the development division with a portfolio of projects focusing on the conversion of biomass to chemical building blocks and plastic materials. The YXY segment comprises the activities of Syviana, the joint venture with BASF SE. The YXY technology is used to convert plant-based sugars into chemical building blocks for plastics, such as polymer polyethylenefuranoate (PEF), and other applications.

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jeroen Van Den Bossche

Thomas Vranken

Wim Hoste

Other Reports on these Companies
Other Reports from KBC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch